Group 1 - KX-826 1.0% treatment for androgenetic alopecia has completed patient enrollment in Phase III clinical trial with a total of 666 patients [1] - The Phase III trial is designed as a seamless II/III phase study, with the II phase achieving primary endpoints with statistical significance and clinical relevance [1] - The trial is multi-center, randomized, double-blind, and placebo-controlled, assessing the efficacy and safety of KX-826 1.0% and 0.5% in Chinese adult male AGA patients [1] Group 2 - Hong Kong Telecom reported a 4% increase in total revenue to HKD 17.322 billion for the first half of the year [2] - Qingdao Bank's net profit for the first half of the year reached CNY 3.065 billion, a year-on-year increase of 16.05% [2] - Green Tea Group expects a profit of CNY 230 million to 237 million for the first half of the year, representing a year-on-year growth of 32% to 36% [2] Group 3 - Hengrui Medicine received approval for clinical trials of HRS-5041 tablets and other drugs [3] - Hengrui also received approval for clinical trials of SHR-8068 injection, Adalimumab injection, and Bevacizumab injection [3] Group 4 - Lee's Pharmaceutical's Socazolimab has been approved for first-line treatment of extensive-stage small cell lung cancer in mainland China [4] - Yihua Holdings plans to sell a property in Weihai for CNY 64.1077 million [4] - Dexin Services Group intends to acquire 100% equity of Deqing Mogan Mountain Ruijun Real Estate [4]
格隆汇公告精选(港股)︱开拓药业-B(09939.HK)：KX-826酊1.0%治疗中国成年男性雄激素脱发关键性临床试验III期阶段达完成全部患者入组